Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells - Takeaways - MDSpire

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells

  • By

  • Hazem Hamza

  • Michael Ghosh

  • Hans-Georg Rammensee

  • Oliver Planz

  • May 26, 2026

  • 0 min

Share

  • 1

    Zapnometinib, a MEK inhibitor, shows antiviral and immunomodulatory activity against Influenza A virus in lung adenocarcinoma cells.

  • 2

    HLA-I surface expression remained unchanged after treatment with zapnometinib and Influenza A virus infection.

  • 3

    Immunopeptidomics revealed significant changes in HLA-I-presented peptides, indicating modulation of the ligandome.

  • 4

    Zapnometinib selectively modulated antiviral responses and cellular pathways without significantly reducing HLA-I levels.

  • 5

    The study supports further investigation of zapnometinib as a host-directed antiviral strategy for targeted immunomodulation.

Original Source(s)

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells

  • by Hazem Hamza, Michael Ghosh, Hans-Georg Rammensee, Oliver Planz

  • May 26, 2026

Related Content

Lung Adenocarcinoma-Induced Leptomeningeal Metastasis Complicated by Lemierre Syndrome: A Case Study and Literature Review

Successful management of severe Pneumocystis jirovecii pneumonia with inhaled nitric oxide and individualized ventilatory strategies in an immunosuppressed patient: a case report

Cough Audio Recognition for Early Detection of Respiratory Diseases: Algorithm Development and Validation Study